2022
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategies
2021
Racial and ethnic disparities among patients with breast cancer and COVID-19.
Nagaraj G, Accordino M, French B, Kuderer N, Lyman G, Stover D, Blinder V, Schmidt A, Shatsky R, Grover P, Puc M, Hwang C, Wulff-Burchfield E, Lewis M, Menendez A, Bilen M, Warner J, Lustberg M, Shah D. Racial and ethnic disparities among patients with breast cancer and COVID-19. Journal Of Clinical Oncology 2021, 39: 6500-6500. DOI: 10.1200/jco.2021.39.15_suppl.6500.Peer-Reviewed Original ResearchCOVID-19 outcomesNon-Hispanic blacksNon-Hispanic whitesHospital admissionClinicopathologic characteristicsMechanical ventilationCancer characteristicsCOVID-19Laboratory-confirmed SARS-CoV-2Worse breast cancer outcomesIntensive care unit admissionCare unit admissionSevere COVID-19Breast cancer outcomesFisher's exact testSignificant differencesSARS-CoV-2High rateEthnic groupsCOVID-19 diagnosisAnti-cancer therapyRace/ethnicityActive diseaseUnit admissionBaseline characteristics
2019
Oncologists' Perceptions of a Digital Tool to Improve Cancer Survivors' Cardiovascular Health
Kelley M, Foraker R, Lin E, Kulkarni M, Lustberg M, Weaver K. Oncologists' Perceptions of a Digital Tool to Improve Cancer Survivors' Cardiovascular Health. ACI Open 2019, 03: e78-e87. PMID: 39149692, PMCID: PMC11326518, DOI: 10.1055/s-0039-1696732.Peer-Reviewed Original ResearchCancer survivorship careSurvivorship careCancer survivorsCV healthCardiovascular healthCare providersHealth promotionPrimary care providersAcademic practice sitesOncologists' perceptionsLeading causeCardiovascular diseaseGeneral populationProvider attitudesPractice sitesHealth toolsNVivo 11 softwareSurvivorsCarePatientsOncologistsHigh rateHealthFurther testingCritical role